IL-6 blockade suppresses the blood-brain barrier disorder, leading to prevention of onset of NMOSD
Y. Takeshita, S. Fujikawa, K. Serizawa, M. Fujisawa, K. Matsuo, J. Nemoto, F. Shimizu, Y. Sano, H. Tomizawa-Shinohara, S. Miyake, R. M. Ransohoff, T. Kanda
The paper shows that IL-6 blockade with satralizumab prevents BBB disruption and lymphocyte migration induced by NMO-IgG in EAE and in vitro BBB models.
bioRxiv · Jan 28, 2021 · PreprintImmunology